2023年度肝癌治疗研究现状与问题

Research status and problems of liver cancer treatment in 2023

原发性肝癌是全球范围内最常见的恶性肿瘤之一,其中约85%为肝细胞癌(简称肝癌)。近年来国内外专家学者进行了大量的临床工作,提出了一系列有潜力的治疗药物和方案,有望进一步提高肝癌患者的疗效和长期生存。本文从外科围手术期治疗领域、系统药物治疗及多学科联合治疗3个大方向对2023年度肝癌治疗研究现状展开综述。

Primary liver cancer is one of the most common malignances worldwide and hepatocellular carcinoma(HCC)represents about 85%.Recent years have witnessed extensive clinical trials by international experts and scholars,which yielding numerous promising drugs and therapeutic strategies for HCC,which are expected to further improve the efficiency andy long-term survival of patients.This paper summaries the progression of HCC treatment from the perspectives of perioperatively surgical interventions,systemic therapy,and multidisciplinary comprehensive treatment in 2023.